esophageal carcinoma esophageal stricture
Conditions
Interventions
After ESD for superficial esophageal cancer, combination therapy with local injection of triamcinolone and oral prednisolone is performed for an off-label purpose.
D014222,D011239
Steroid injection with oral administration
Sponsors
Kakushima Naomi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as esophageal carcinoma. 2. Depth up to cT1b(SM1, =1/2 circumference or simultaneous resection of multiple adjacent lesions which are expected to have ulcer with >3/4 circumference after ESD. 5. Patients who are indicated and scheduled for esophageal ESD. 6. ECOG performance status of 0 or1. 7. Age >= 18. 8. Patients who provide written informed consent. 9. Patients who can go to the outpatient clinic according to the clinical research schedule
Exclusion criteria
Exclusion criteria: 1. Diabetes Mellitus with HbA1c >=8%. 2. Severe liver, renal, cardiovascular disease. 3. Patients who are receiving continuous systemic administration of steroids or other immunosuppressants at the time of informed consent 4. Patients with infectious diseases that require systemic treatment. 5. Patients who have allergy to triamcinolone, prednisolone, and sulfamethoxazole trimethoprim. 6. Patients taking desmopressin acetate. 7. Patients who have active HBV hepatitis. 8. Patients who are pregnant. 9. Patients who the investigator judges inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Esophageal non-stenosis rate up to 12 weeks after ESD | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Number of endoscopic dilations for esophageal stenosis up to 12 weeks after ESD. 2. Stenosis-free period after ESD. 3. Rate of adverse events | — |
Contacts
Public ContactNaomi Kakushima
The University of Tokyo Hospital
Outcome results
None listed